Another treatment option for ovarian cancer approved for the Cancer Drugs Fund
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
-
NICE looks to company to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
-
Migraine drug not cost effective NICE says in final draft guidance
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in final draft guidance published today (26 September 2019).
-
More than one thousand neonatal admissions could be avoided per year by following NICE guidance
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
